Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Short term Debt (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Short term Debt for 4 consecutive years, with $539000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt fell 66.77% to $539000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $539000.0, a 66.77% decrease, with the full-year FY2024 number at $1.6 million, changed 0.0% from a year prior.
  • Short term Debt was $539000.0 for Q3 2025 at Spruce Biosciences, down from $943000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.6 million in Q4 2022 to a low of $405000.0 in Q1 2022.
  • A 4-year average of $1.3 million and a median of $1.6 million in 2022 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: skyrocketed 300.49% in 2023, then plummeted 66.77% in 2025.
  • Spruce Biosciences' Short term Debt stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then tumbled by 66.77% to $539000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Short term Debt are $539000.0 (Q3 2025), $943000.0 (Q2 2025), and $1.3 million (Q1 2025).